Ist die Serumkonzentration von Pentosidin ein Prädiktor kardiovaskulärer Ereignisse bei Patienten mit Diabetes mellitus Typ 2 und Nephropathie?

Zusammenfassung

Hintergrund und Fragestellung: „Advanced glycation endproducts” (AGEs) gelten als Mediatoren der Gefäßschädigung bei der Atherosklerose, besonders bei Diabetes und Niereninsuffizienz. Korreliert das AGE Pentosidin, das durch Glykierung und anschließende Oxidation gebildet (Glykoxidationsprodukt) wird, bei Patienten mit Diabetes mellitus Typ 2 und Nephropathie mit kardiovaskulären Ereignissen?

Patienten und Methodik: 218 kardiovaskuläre Hochrisikopatienten der „Irbesartan in Diabetic Nephropathy Trial” (IDNT)-Studienpopulation mit Typ-2-Diabetes und Nephropathie (mittleres Alter 61 ± 6,4 Jahre, 68 weiblich, 150 männlich) sowie einer mittleren GFR von 47,9 ± 16,0 ml/min (nach MDRD Formel) wurden für im Mittel 2,2 Jahre beobachtet. Pentosidin wurde mittels Hochdruck-Flüssigkeitschromatographie bestimmt. Der Zusammenhang zwischen Pentosidin, traditionellen Risikofaktoren sowie kardiovaskulären Ereignissen wurde mit der Cox-Regressionsanalyse geprüft.

Ergebnisse: Die Pentosidin-Serumkonzentration betrug zu Beginn der Studie 148 ± 113 pmol/ml, die von HbA_1c 8,6 ± 1,7 %. Insgesamt traten 93 kardiovaskuläre Ereignisse auf; 50 Patienten starben, davon 39 an kardiovaskulären Ursachen. Low-density-lipoprotein (LDL) und Diabetesdauer erwiesen sich in einer multivariaten Analyse als unabhängige Risikofaktoren für ein erstes kardiovaskuläres Ereignis (einschließlich kardiovaskulärer Tod) (relatives Risiko (RR) für das höchste, verglichen mit dem niedrigsten Quartil für LDL: 3,041, Konfidenzintervall 1,616 - 5,724, P = 0,001; für Diabetesdauer: RR 2,629, KI 1,279 - 6,151, P = 0,011).

Folgerung: Die Serumkonzentration von Pentosidin konnte in der untersuchten Studienpopulation nicht als unabhängiger Risikofaktor für kardiovaskuläre Endpunkte identifiziert werden. Dieses Ergebnis legt nahe, dass konventionelle Risikofaktoren eine bedeutendere Rolle für kardiovaskuläre Ereignisse spielen, während AGE-Serumkonzentrationen eher von untergeordnetem prädiktivem Wert sind. Ob AGE-Gewebsspiegel von größerer Relevanz sein könnten, ist derzeit Gegenstand der Diskussion.

Summary

Background and objective: Advanced glycation end-products (AGEs) are implicated in the pathogenesis of vascular damage of atherosclerosis, especially in diabetes and renal failure. Pentosidine, an AGE, is generated by glycation and oxidation reactions (glycoxidation product).

Methods: 218 patients at high risk of cardiovascular events (from the „Irbesartan in Diabetic Nephropathy Trial” [IDNT] cohort) with type 2 diabetes and nephropathy (mean age 61 ± 6,4 years, 68 female, 150male) were followed for a mean of 2.2 years. The mean GFR at baseline was 47,9 ± 16,0 ml/min (MDRD formula). Serum levels of pentosidine were measured by high-performance liquid chromatography. The relationship between pentosidine, traditional risk factors and cardiovascular events (CVE) was tested in Cox proportional hazards models.

Results: The mean serum level of pentosidine at baseline was 148 ± 113 pmol/ml, that of hemoglobin A_1c (HbA_1c) 8.6 ± 1.7 %. During follow-up, 93 CVE occurred; a total of 50 patients died, 39 of cardiovascular causes. Final multivariate analysis showed low density lipoprotein (LDL) and duration of diabetes to be independent risk factors for a first cardiovascular event (including death from cardiovascular causes) (relative risk [RR] for the highest quartile compared with the lowest: LDL 3,041, confidence interval 1.616 - 5.724, P = 0.001; duration of diabetes: RR 2.629, CI 1.279 - 6.151, P = 0.011).

Conclusion: The serum level of pentosidine was not an independent risk factor for cardiovascular outcomes in the selected cohort. This suggests that traditional risk factors may play a more important role in causing cardiovascular events and that serum levels of AGEs are of low predictive value. Further investigations are necessary to assess whether tissue levels of AGEs are of greater relevance.

chronische Niereninsuffizienz - kardiovaskuläres Risiko - advanced glycation endproducts - Pentosidin - diabetische Nephropathie

chronic renal failure - cardiovascular risk - advanced glycation endproducts - pentosidine - diabetic nephropathy

Literatur

• 1 Anavekar N S, Gans D J, Pfeffer M A. et al . Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.  Kidney Int. 2004;  (Suppl 92) 66 S50-55
• 2 Baynes J W, Thorpe S R. Role of oxidative stress in diabetic complications.  Diabetes. 1999;  48 1-9
• 3 Berl T, Hunsicker L G, Lewis E J. et al, for the Collaborative Study Group . Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.  Ann Intern Med. 2003;  138 542-549
• 4 Best J D, O`Neal D N. Diabetic dyslipidemia: current treatment recommendations.  Drugs. 2000;  59 1101-1111
• 5 Bierhaus A, Hofmann M A, Ziegler R, Nawroth P P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus I. The AGE concept.  Cardiovasc Res. 1998;  37 586-600
• 6 Bohlender J M, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney.  Am J Physiol Renal Physiol. 2005;  289 645-659
• 7 Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.  J Clin Invest. 1991;  87 432-438
• 8 Busch M, Franke S, Stein G. et al . Potential cardiovascular risk factors in chronic kidney disease; AGEs, total homocysteine and metabolites, and the C-reactive protein.  Kidney Int. 2004;  66 338-347
• 9 Busch M, Franke S, Wolf G. et al . The advanced glycation end product Ne-carboxymethyllysine is not a predictor of cardiovascular events and renal outcome in patients with type 2 diabetic kidney disease and hypertension.  Am J Kidney Dis. 2006;  48 571-579
• 10 Fu M X, Requena J R, Jenkins A J, Lyons T J, Baynes J W, Thorpe S R. The advanced glycation end product, Ne-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions.  J Biol Chem. 1996;  17 9982-9986
• 11 Gaede P, Vedel P, Larsen N. et al . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
• 12 Genuth S, Sun W, Cleary P. et al . Glycation and carboxymethyllysine levels in skin collagen predict the risk of 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.  Diabetes. 2005;  54 3103-3111
• 13 Goldin A, Beckman J A, Schmidt A M, Creager M A. Advanced glycation end products sparking the development of diabetic vascular injury.  Circulation. 2006;  114 597-605
• 14 Hosmer D W, Lemeshow S. Applied survival analysis: regression modelling of time to event data. New York, John Wiley and Sons, Inc 1999
• 15 Hricik D E, Wu Y C, Schulak A, Friedlander M A. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.  Clin Transplant. 1996;  10 568-573
• 16 Koschinsky T, He C J, Mitsuhashi T. et al . Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy.  Proc Natl Acad Sci. 1997;  94 6474-6479
• 17 Koyama Y, Takeishi Y, Arimoto T. et al . High serum levels of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.  J Cardiac Failure. 2007;  13 199-206
• 18 Lapolla A, Reitano R, Baccarin L, Sartore G, Plebani M, Fedele D. Pentosidine plasma levels and relation with metabolic control in diabetic patients.  Horm Metab Res. 2005;  37 252-256
• 19 Levey A S, Bosch J P, Lewis J B. et al . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.  Ann Intern Med. 1999;  330 461-470
• 20 Lewis E J, Hunsicker L G, Raz I. et al . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.  N Engl J Med. 2001;  345 851-860
• 21 Locatelli F, Bommer J, London G M. et al . Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment.  Nephrol Dial Transplant. 2001;  16 459-468
• 22 Meerwaldt R, Graaff R, Oomen P HN. et al . Simple non-invasive assessment of advanced glycation endproduct accumulation.  Diabetologia. 2004;  47 1324-1330
• 23 Meerwaldt R, Hartog J WL, Graaff R. et al . Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation and products, predicts mortality in hemodialysis patients.  J Am Soc Nephrol. 2005;  16 3687-3693
• 24 Minutolo R, Sasso F C, Chiodini P. et al . Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings.  J Hypertens. 2006;  24 1655-1661
• 25 Miyata T, Ueda Y, Maeda K. et al . Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine.  J Am Soc Nephrol. 1996;  7 1198-1206
• 26 Miyata T, Fu M, Kurokawa K, van Ypersele de Strihou C, Thorpe S R, Baynes J W. Autooxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia?.  Kidney Int. 1998;  54 1290-1295
• 27 Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes J W. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of „carbonyl stress” in long-term uremic complications.  Kidney Int. 1999;  55 389-399
• 28 Rodby R A, Rohde R D, Lewis E J. et al . The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics.  Nephrol Dial Transplant. 2000;  15 487-497
• 29 Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure.  Nephron. 2002;  91 64-73
• 30 Schleicher E D, Wagner E, Nerlich A G. Increased accumulation of the glycoxidation product Ne-(carboxymethyl)lysine in human tissues in diabetes and aging.  J Clin Invest. 1997;  99 457-468
• 31 Schwedler S B, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients.  Kidney Int. 2002;  62 301-310
• 32 Stein G, Busch M, Franke S. et al . Are advanced glycation end products cardiovascular risk factors in patients with CRF?.  Am J Kidney Dis. 2003;  41 (Suppl 1) S52-S56
• 33 Suliman M E, Heimbürger O, Barany P, Anderstam B, Pecoits-Filho R, Ayala E R, Qureshi A R, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.  J Am Soc Nephrol. 2003;  14 1614-1622
• 34 Wanner C, Krane V, März W. et al . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.  N Engl J Med. 2005;  353 238-248
• 35 Weiss M F, Erhard P, Kader-Attia F A. et al . Mechanisms for the formation of glycoxidation products in end-stage renal disease.  Kidney Int. 2000;  57 2571-2585